Status:

COMPLETED

Detection of Coronary Vulnerable Plaque With Contrast-enhanced Magnetic Resonance Imaging

Lead Sponsor:

Maastricht University Medical Center

Collaborating Sponsors:

Bayer

Conditions:

Coronary Artery Disease

Stable Angina

Eligibility:

All Genders

18-90 years

Phase:

NA

Brief Summary

MRI has the ability to visualize the arterial vessel wall. Wall thickening and atherosclerotic plaque components can be visualized in the carotid arteries and the aorta. Previous studies also demonstr...

Eligibility Criteria

Inclusion

  • scheduled X-ray angiography for known coronary artery disease, valvular disease or chest pain with unknown origin
  • age \> 18 yrs and \< 90 yrs
  • Informed consent

Exclusion

  • arrhythmia
  • hemodynamic unstable patients
  • contra-indications for (contrast-enhanced) MRI
  • age \< 18 yrs or \> 90 yrs

Key Trial Info

Start Date :

March 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT00984776

Start Date

March 1 2007

Last Update

September 25 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Maastricht University Medical Center

Maastricht, Netherlands, 6229 HX

Detection of Coronary Vulnerable Plaque With Contrast-enhanced Magnetic Resonance Imaging | DecenTrialz